Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NYSEAMERICAN:PTN

Palatin Technologies Q1 2027 Earnings Date & Estimates

Palatin Technologies logo
$4.82 -0.29 (-5.68%)
Closing price 10/26/2026 04:00 PM Eastern
Extended Trading
$4.83 +0.01 (+0.12%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palatin Technologies is estimated to report Q1 2027 earnings on Monday, November 16, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 11:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q1 2027
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
11:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Palatin Technologies in Q1 2027

Palatin Technologies is expected to post earnings of -$0.42 per share on revenue of $2.51 million. Palatin Technologies last reported on September 28, 2026, posting -$1.11 per share and beating the -$1.20 consensus estimate.

Consensus Estimates

Consensus EPS
-$0.42
Expected Revenue
$2.51 million

Recent Track Record

Last Reported
Sep 28, 2026
Last Quarter EPS
-$1.11 (Beat by +$0.09)
Last Quarter Revenue
$301 thousand

Prepare for the Q1 2027 Call

Palatin Technologies Q1 2027 Earnings FAQ

Palatin Technologies (NYSEAMERICAN:PTN) is estimated to report Q1 2027 earnings on Monday, November 16, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Palatin Technologies' Q1 2027 earnings conference call is scheduled for Thursday, November 12, 2026 at 11:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Palatin Technologies to post earnings of -$0.42 per share for Q1 2027.

The consensus revenue estimate for Palatin Technologies is $2.51 million for Q1 2027.

Palatin Technologies Earnings Headlines

Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)
October 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/big-pharma-s-obesity-shopping-spree-is-moving-beyond-glp-1s-palatin-may-fit-the-pattern-nasdaq-ptn-1036650448
Palatin Technologies (NYSEAMERICAN:PTN) Stock Price Down 7.8% - Should You Sell?
October 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141530
80 Days Until America's Rare Earth Supply Chain Shift
China controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports to the U.S. With a January 1, 2027 deadline approaching, the Pentagon selected four companies to build critical mineral processing facilities on U.S. military bases. Only one was chosen for heavy rare earths - a Nasdaq-listed firm with an Ohio metallurgy facility under Pentagon contracts and rights to 80% of output from a major Canadian processing plant.tc pixel
October 27 at 1:00 AM  |  The Tomorrow Investor (Ad)
Palatin Technologies Earnings Call: Science vs. Cash
September 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/palatin-technologies-earnings-call-science-vs-cash?utm_source=marketbeat.com&utm_medium=referral
Palatin (PTN) Q4 2026 Earnings Call Transcript
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/palatin-ptn-q4-2026-earnings-071427969.html
Palatin Technologies Q4 Loss Widens From Higher Expenses; Shares Down
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694451/palatin-technologies-q4-loss-widens-from-higher-expenses-shares-down.aspx
See More Palatin Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palatin Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palatin Technologies and other key companies, straight to your email.

About Palatin Technologies

Palatin Technologies (NYSEAMERICAN:PTN), Inc. is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, a group of receptors involved in regulating inflammation, immune responses, metabolism and sexual function. The company’s research programs are designed to address conditions for which targeted therapies may offer an alternative to existing treatments.

Palatin’s most recognized product is Vyleesi (bremelanotide), a melanocortin receptor agonist approved by the U.S. Food and Drug Administration for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. Palatin developed the therapy and has pursued commercialization through licensing and partnering arrangements.

The company has also developed investigational compounds, including PL8177, a melanocortin-1 receptor agonist studied for inflammatory and immune-related disorders, and PL9643, an investigational treatment evaluated for ocular conditions such as dry eye disease. Palatin is headquartered in Cranbury, New Jersey, and has historically advanced its programs through internal research, clinical development and collaborations with pharmaceutical partners.

View Palatin Technologies Profile
Earnings Tools